Emma Walmsley, GlaxoSmithKline CEO (Fang Zhe/Xinhua/Alamy Live News)

GSK and Vir turn to US for dis­tri­b­u­tion as Covid-19 mAb treat­ment nears block­buster sta­tus

Ever since for­mer Pres­i­dent Trump re­ceived an in­fu­sion of Re­gen­eron’s mon­o­clon­al an­ti­body, all three of the now-au­tho­rized Covid-19 mAb treat­ments have been in the spot­light.

The on­ly one fly­ing some­what un­der the radar is al­so the one to most re­cent­ly re­ceive an emer­gency au­tho­riza­tion, which came last May for Glax­o­SmithK­line and Vir Biotech­nol­o­gy’s mAb sotro­vimab. But that third-to-mar­ket sta­tus hasn’t stopped the com­pa­nies from quick­ly sell­ing about $1 bil­lion worth of dos­es in the first six months and re­cent­ly sign­ing a $280 mil­lion US gov­ern­ment con­tract.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.